Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWAP-8: DAPT De-escalation by Dose Reduction vs Switching in PCI
NCT06821191Phase 4Recruiting
- Sponsor
- University of Florida
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of prasugrel in coronary artery disease (CAD) (2 arms), sponsored by University of Florida. Primary endpoint: Platelet reactivity measured by VerifyNow at 30 days. Started Mar 2025; status: recruiting.
02
Drugs
prasugrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06821191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821191.